Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03908671
Other study ID # STZD-1801
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 18, 2019
Est. completion date December 31, 2025

Study information

Verified date April 2023
Source Stemirna Therapeutics
Contact Li Yang
Phone 0371-66295320
Email yanglizzuyl@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal cancer and non-small cell lung cancer


Description:

Primary objectives: Assessing the safety and tolerability of mRNA personalized tumor vaccines encoding neoantigen for unresectable or metastatic advanced esophageal and non-small cell lung cancers with standard treatment failure or no standard treatment. Secondary objectives: Preliminary observation of the efficacy of mRNA personalized tumor vaccines encoding neoantigen for unsurgically resected or metastatic advanced esophageal and non-small cell lung cancers with standard treatment failure or no standard treatment. Time of tumor progression (TTP); Disease Control Rate (DCR); Objective Remission Rate (ORR); Overall Survival (OS).


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date December 31, 2025
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Aged between 18 and 75 (including both ends), with no gender limit; - The primary lesion was confirmed by histopathology or cytology as esophageal carcinoma (?C (T4bNanyM0, TanyN3M0), and stage ?) or non-small cell lung cancer (stage ?B-?). - Patients who have metastatic or locally advanced tumor but failed instandard treatments or not suitable for standard treatments; - According to RECIST (V1.1), the efficacy evaluation criteria for solid tumors, there is at least one measurable lesion. - Participants with Performance Scale (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) PS - Participants must have at least 1 lesion amenable to the mandatory fresh tumor biopsy at study entry - Fertile patients must agree to use a reliable contraceptive methods (hormonal or barrier methods or abstinence) during the trial and for at least 12 weeks after the last treatment; - The subject voluntarily participates and signs ICF (Informed consent forms). Exclusion Criteria: - Any clinical research drugs, anti-cancer monoclonal antibodies, anti-cancer therapeutic vaccines, immunostimulants (such as IL-2) or using previous investigational drugs within 7 days of the first treatment with mRNA-personalized tumor vaccine or carrelizumab. - Patients who have allergies or previous history of biological drug allergy; - Patients who are in pregnant or breast-feeding; - Patients who are expected to survive less than 3 months during the screening period; - Tumor mutation load (TMB) is less than 2.0/Mb or tumor neogenic antigen load (TNB) is less than 0.5/Mb or the number of predicted neoantigen is less than 3; - Patients who underwent major surgery or suffered significant trauma within 4 weeks prior to the enrollment (blood collection), or who are expected to undergo major surgery during the study period; - Patients with symptoms of brain metastases (Patients with stable brain metastases can be included) - Extensive lung metastases from tumors, causing breathing difficulties; - Patients who have tumors close to large blood vessels or nerves; - A history of severe cardiovascular and cerebrovascular diseases, including but not limited to ventricular arrhythmia requiring clinical intervention; Acute coronary syndrome, myocardial infarction, congestive heart failure, stroke or other grade III and above cardiovascular events within 6 months; New York Heart Association (NYHA) cardiac function grade=Grade II or left ventricular ejection fraction (LVEF) <50%; Poorly controlled hypertension after standard treatment (systolic blood pressure> 150 mmHg and diastolic blood pressure> 90 mmHg); - Patients with active ulcers and gastrointestinal bleeding; - Patients with clinically confirmed autoimmune disease have received systemic treatment in the past 2 years; HIV, HCV positive; HBV-DNA=1×103 copies/mL (or 2×102 IU/mL); Acute EBV or CMV virus infection; - Patients with previous history of non-infectious pneumonia requiring steroid therapy or acute lung cancer; - Participants with a history of interstitial lung disease; - Patients who have a history of organ transplantation or are waiting for organ transplantation; - Have any uncontrolled active infection; - Immunosuppressed subjects, including those with known immunodeficiency; those who are currently using steroids systemically (except those who are using inhaled steroids recently or currently); - Skin diseases (such as psoriasis) may prevent intradermal vaccines from reaching the target area; - Who have received chemotherapy, biotherapy, radiotherapy, endocrine therapy, targeted therapy and other tumor treatments, or other experimental drug treatments, or surgery (excluding diagnostic biopsy) within 7 days prior to the first administration of mRNA tumor vaccine treatment; - Adverse effects from previous antitumor therapy have not recovered referred to CTCAE (V5.0) rating =1 (except hair loss); - The investigator evaluates that the subject is unable or unwilling to comply with the requirements of study protocol.

Study Design


Intervention

Biological:
Personalized mRNA Tumor Vaccine
subcutaneous injection with personalized mRNA tumor vaccine

Locations

Country Name City State
China The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan

Sponsors (2)

Lead Sponsor Collaborator
Stemirna Therapeutics The First Affiliated Hospital of Zhengzhou University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 During the trial conduction, especially within the 24 weeks of treatment phase when mRNA tumor Vaccine administered, all adverse events (including laboratory abnormality and clinical events) will be closely monitored, and all = grade 3 adverse events per CTCAE will be recorded, including but not limited to the toxicities potentially suspected to relate to injection procedures and/or mRNA Tumor Vaccine therapy as listed below:
Fever Chills Nausea, vomiting and other gastrointestinal symptoms Fatigue Hypotension Respiratory distress Tumor lysis syndrome Neutropenia, thrombocytopenia Liver and kidney dysfunction Neutropenia, thrombocytopenia Liver and kidney dysfunction
24 weeks
Secondary Disease Control Rate (DCR) Disease Control Rate of Personalized mRNA Tumor Vaccine 1.5 years
Secondary Progression-free Survival (PFS) Progression-free Survival of Personalized mRNA Tumor Vaccine 2 years
Secondary Time to Tumor Progression (TTP) Time to Tumor Progression of Personalized mRNA Tumor Vaccine 2 years
Secondary Overall Survival (OS) Overall Survival of Personalized mRNA Tumor Vaccine 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting NCT05542680 - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer N/A
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT00003864 - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus Phase 2
Recruiting NCT05491616 - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed NCT00400114 - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04615806 - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy N/A
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Terminated NCT01446874 - Prevention of Post-operative Pneumonia (POPP) Phase 2/Phase 3
Completed NCT03468634 - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy N/A
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT01404156 - Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma Phase 2/Phase 3